Johnson & Johnson (NYSE:JNJ) Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH reduced its stake in Johnson & Johnson (NYSE:JNJ) by 12.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,489,208 shares of the company’s stock after selling 213,366 shares during the period. Johnson & Johnson makes up about 1.5% of Fort Washington Investment Advisors Inc. OH’s holdings, making the stock its 12th largest holding. Fort Washington Investment Advisors Inc. OH owned about 0.06% of Johnson & Johnson worth $246,970,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Farrell Financial LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $211,000. Allen Mooney & Barnes Investment Advisors LLC grew its position in shares of Johnson & Johnson by 2.2% during the first quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 8,469 shares of the company’s stock worth $1,404,000 after buying an additional 186 shares in the last quarter. Ferguson Wellman Capital Management Inc. increased its stake in shares of Johnson & Johnson by 1.0% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 282,317 shares of the company’s stock worth $46,820,000 after buying an additional 2,694 shares during the period. Defined Financial Planning LLC raised its holdings in Johnson & Johnson by 10.9% in the first quarter. Defined Financial Planning LLC now owns 2,991 shares of the company’s stock valued at $458,000 after acquiring an additional 293 shares in the last quarter. Finally, FMB Wealth Management purchased a new position in Johnson & Johnson in the first quarter worth approximately $233,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on JNJ. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $156.61 on Friday. The company has a market cap of $376.82 billion, a price-to-earnings ratio of 23.55, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a fifty day moving average price of $153.69 and a 200 day moving average price of $153.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.32%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.